BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

bioMerieux, Inc. BacT/ALERT(R) 3D Wins Key Role In Platelet Collection System


10/19/2005 5:13:11 PM

DURHAM, N.C., April 1 /PRNewswire/ -- bioMerieux, a world leader in the field of in vitro diagnostics for medical and industrial applications, today announced that its BacT/ALERT(R) 3D Microbial Detection System will play an integral role in a leading Single Donor Platelet Technology system. Gambro BCT, Inc., recently received clearance by the U.S. Food and Drug Administration (FDA) for apheresis platelets to be collected with its Trima(R) and COBE Spectra(TM) Collection Systems for routine storage and patient transfusion up to seven days. Clearance was obtained on the condition that the platelets are tested with the bioMerieux BacT/ALERT Microbial Detection System, and used as described in the Gambro BCT seven-day platelet protocol.

The FDA clearance will now allow blood banks that use the Gambro BCT system to store single donor platelets for up to seven days. Previously, platelets had to be transfused within five days of collection due to concerns about bacterial contamination. The short shelf life of platelets creates continuing challenges for blood suppliers to meet transfusion needs. The two- day extension of platelet shelf life will have a positive impact on United States platelet supply.

"Bacterial contamination of blood is a serious threat, and the blood community is very diligent about advancing testing of blood components for aerobic and anaerobic organisms," said Eric Bouvier, president and CEO, bioMerieux, Inc. "BacT/ALERT is a proven system that is currently being used by most U.S. blood banks for testing microbial contamination and we're very proud of BacT/ALERT's role in such a significant advancement in platelet shelf life."

BacT/ALERT 3D is a state-of-the-art, automated microbial detection system that integrates blood, sterile body fluid and mycobacteria culturing. In addition to its space-saving modular design, easy touch-screen operation and flexible data management options, BacT/ALERT 3D utilizes industry-exclusive plastic BacT/ALERT bottles. These unique plastic bottles are designed to help laboratories better adhere to the U.S. Department of Occupational Safety and Health Administration (OSHA) Blood Borne Pathogens Standard and other regulatory mandates. The BacT/ALERT bottles help protect laboratory and hospital staff from the risk of hazardous sharp exposure and accidental injury. Safety is a key factor in blood platelet collection, since over 70 percent of the annual 2.2 million platelet transfusions in the U.S. are done through apheresis and incorporate contaminant testing.

About bioMerieux

bioMerieux, Inc. is the U.S. subsidiary of bioMerieux S.A., a company headquartered in France. bioMerieux is a leading international diagnostics group that specializes in the field of in vitro diagnostics for clinical and industrial applications. bioMerieux designs, develops, manufactures and markets systems (i.e. reagents, instruments and software) used in:

Clinical applications: the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancer, based on the analysis of biological samples (such as blood, saliva or urine); and

Industrial applications: the microbiological analysis of food, environments (such as water and air), surfaces and pharmaceutical and cosmetic products, based on the analysis of product or environmental samples. bioMerieux has pioneered this business and is the world leader.

In 2004, the company's sales reached 931 million euros (i.e., more than one billion dollars) and eighty-two percent of the company's sales are international. The company is present in more than 130 countries through 33 subsidiaries and a large network of distributors, which positions the company well to benefit from the growth potential of the in vitro diagnostics market. Some important drivers that underpin this growth are aging populations and age-related illness, illnesses related to life-style and eating habits, emerging pathogens, the development of antibiotic-resistant bacteria, the fight against bio-terrorism, the recognition of the importance of the quality of food products, cosmetics and pharmaceuticals. The company employs more than 5,300 people worldwide.

bioMerieux is listed on the Premier Marche of Euronext, Paris (FR0010096479 - BIM). For more information, visit the web site at http://www.biomerieux-usa.com/ .

bioMerieux, Inc.

CONTACT: Sean Graham of French West Vaughan, +1-919-832-6300, orsgraham@fwv-us.com , for bioMerieux


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->